vs
Side-by-side financial comparison of Armour Residential REIT, Inc. (ARR) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $50.4M, roughly 1.2× Armour Residential REIT, Inc.). Armour Residential REIT, Inc. runs the higher net margin — 420.2% vs -70.9%, a 491.2% gap on every dollar of revenue. On growth, Armour Residential REIT, Inc. posted the faster year-over-year revenue change (297.9% vs 8.1%). Over the past eight quarters, Armour Residential REIT, Inc.'s revenue compounded faster (108.0% CAGR vs 17.7%).
Armour Residential REIT, Inc. is a U.S.-based real estate investment trust that primarily invests in agency residential mortgage-backed securities guaranteed by U.S. government-sponsored entities. It focuses on generating consistent long-term net income for shareholders via strategic asset management and active interest rate risk mitigation.
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
ARR vs CTKB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $50.4M | $62.1M |
| Net Profit | $211.7M | $-44.1M |
| Gross Margin | — | 52.9% |
| Operating Margin | — | -9.0% |
| Net Margin | 420.2% | -70.9% |
| Revenue YoY | 297.9% | 8.1% |
| Net Profit YoY | 555.9% | -557.1% |
| EPS (diluted) | $2.43 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $50.4M | $62.1M | ||
| Q3 25 | $38.5M | $52.3M | ||
| Q2 25 | $33.1M | $45.6M | ||
| Q1 25 | $36.3M | $41.5M | ||
| Q4 24 | $12.7M | $57.5M | ||
| Q3 24 | — | $51.5M | ||
| Q2 24 | $7.0M | $46.6M | ||
| Q1 24 | — | $44.9M |
| Q4 25 | $211.7M | $-44.1M | ||
| Q3 25 | $159.3M | $-5.5M | ||
| Q2 25 | $-75.6M | $-5.6M | ||
| Q1 25 | $27.3M | $-11.4M | ||
| Q4 24 | $-46.4M | $9.6M | ||
| Q3 24 | — | $941.0K | ||
| Q2 24 | $-48.4M | $-10.4M | ||
| Q1 24 | — | $-6.2M |
| Q4 25 | — | 52.9% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 52.3% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 58.5% | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 54.6% | ||
| Q1 24 | — | 51.3% |
| Q4 25 | — | -9.0% | ||
| Q3 25 | — | -17.6% | ||
| Q2 25 | — | -23.3% | ||
| Q1 25 | — | -36.1% | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | — | -8.2% | ||
| Q2 24 | — | -18.3% | ||
| Q1 24 | — | -23.9% |
| Q4 25 | 420.2% | -70.9% | ||
| Q3 25 | 413.5% | -10.5% | ||
| Q2 25 | -228.4% | -12.2% | ||
| Q1 25 | 75.2% | -27.5% | ||
| Q4 24 | -366.8% | 16.8% | ||
| Q3 24 | — | 1.8% | ||
| Q2 24 | -693.8% | -22.4% | ||
| Q1 24 | — | -13.8% |
| Q4 25 | $2.43 | — | ||
| Q3 25 | $1.49 | — | ||
| Q2 25 | $-0.94 | — | ||
| Q1 25 | $0.32 | — | ||
| Q4 24 | $-0.91 | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.05 | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $63.3M | $90.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3B | $341.7M |
| Total Assets | $21.0B | $461.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $63.3M | $90.9M | ||
| Q3 25 | $44.2M | $93.3M | ||
| Q2 25 | $141.2M | $75.5M | ||
| Q1 25 | $49.1M | $95.3M | ||
| Q4 24 | $68.0M | $98.7M | ||
| Q3 24 | — | $162.3M | ||
| Q2 24 | $126.6M | $177.9M | ||
| Q1 24 | — | $168.8M |
| Q4 25 | $2.3B | $341.7M | ||
| Q3 25 | $2.1B | $378.6M | ||
| Q2 25 | $1.7B | $377.6M | ||
| Q1 25 | $1.7B | $379.6M | ||
| Q4 24 | $1.4B | $395.7M | ||
| Q3 24 | — | $385.5M | ||
| Q2 24 | $1.2B | $389.1M | ||
| Q1 24 | — | $392.6M |
| Q4 25 | $21.0B | $461.5M | ||
| Q3 25 | $19.4B | $494.9M | ||
| Q2 25 | $16.2B | $493.3M | ||
| Q1 25 | $15.5B | $482.6M | ||
| Q4 24 | $13.5B | $499.5M | ||
| Q3 24 | — | $491.2M | ||
| Q2 24 | $10.1B | $483.7M | ||
| Q1 24 | — | $492.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $124.2M | $-771.0K |
| Free Cash FlowOCF − Capex | — | $-1.8M |
| FCF MarginFCF / Revenue | — | -2.9% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | 0.59× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-8.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $124.2M | $-771.0K | ||
| Q3 25 | $-37.8M | $-3.9M | ||
| Q2 25 | $25.0M | $108.0K | ||
| Q1 25 | $101.5M | $-125.0K | ||
| Q4 24 | $261.5M | $2.0M | ||
| Q3 24 | — | $13.2M | ||
| Q2 24 | $27.1M | $6.2M | ||
| Q1 24 | — | $4.0M |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-4.6M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-974.0K | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $12.2M | ||
| Q2 24 | — | $5.2M | ||
| Q1 24 | — | $3.4M |
| Q4 25 | — | -2.9% | ||
| Q3 25 | — | -8.7% | ||
| Q2 25 | — | -3.2% | ||
| Q1 25 | — | -2.3% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 23.7% | ||
| Q2 24 | — | 11.0% | ||
| Q1 24 | — | 7.6% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | 0.59× | — | ||
| Q3 25 | -0.24× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.71× | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | 14.05× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARR
Segment breakdown not available.
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
